
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Mol. Neurosci.
Sec. Molecular Signalling and Pathways
Volume 18 - 2025 | doi: 10.3389/fnmol.2025.1567453
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Propofol is a commonly used intravenous anesthetic in clinical practice, while ciprofol, a propofol derivative, also targets GABAA receptors with enhanced anesthetic potency.Regarding chronopharmacology, it remains unclear whether the new drug ciprofol has improved anesthetic effect and less side effects compared with propofol. First, we assessed the critical anesthetic dosage (Dca) of ciprofol and propofol exhibited diurnal rhythmicity. At the highest Dca, the loss of righting reflex duration was significantly longer for ciprofol than that for propofol at both Zeitgeber Time (ZT) 4 and ZT16. The β3 subunits of the GABAA receptor, which are involved in mediating anesthetic effects, and the metabolizing enzyme UGT1A9 for propofol demonstrated rhythmic expression. Moreover, molecular dynamics simulation indicated a higher binding affinity of R-ciprofol to GABRB3 compared with propofol. Animal behavior experiments indicated that ciprofol was associated with no incidence of side effects at any time of day, while propofol exhibited circadian-related adverse effects. Notably, ciprofol infrequently disrupted the rhythmicity of clock gene expression compared to propofol. From a chronopharmacological perspective, ciprofol offers improved sedation and fewer side effects compared to propofol, suggesting its higher potential for clinical application.
Keywords: Chronopharmacology, Ciprofol, critical anesthesia dosage, drug distribution, GABAAR, Propofol
Received: 27 Jan 2025; Accepted: 19 Mar 2025.
Copyright: © 2025 Li, Yang, Chen, Yu, Wang, Liu, He, Shu, Duan, Zhang, Ju and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
He Huang, Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.